| Abstrakt: |
BaroFold, Inc, a leader in high pressure protein refolding, and Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, today announced that they have entered into a non-exclusive technology and commercial license option agreement. Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold’s Pressure Enabled Manufacturing Technology (PreEMTTM) that can also be qualified for GMP use. The technology will be installed at Boehringer Ingelheim’s microbial facility in Vienna, Austria and will be available for development of biopharmaceutical production processes. [ABSTRACT FROM PUBLISHER] |
